Progress in acute myeloid leukemia
- Tapan M. Kadia(corresponding author),
- Farhad Ravandi,
- Susan O'Brien,
- ,
- Hagop M. Kantarjian
- University of Texas Health Science Center at Houston
Scholary Output:
Contribution to journal
Review article
Peer-review
Open access
Sustainable Development Goals
SDG 3 Good Health and Well
Abstract
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 139-151 (13 pages)Journal (Volume, Issue Number)
Clinical Lymphoma, Myeloma and Leukemia (Volume 15, Issue 3)Publication milestones
- Published - 03/01/2015
Publication status
Published - 03/01/2015
ISSN
2152-2650Publication IDs
- Scopus: 84923574693
- PubMed: 25441110
Publication metrics
Metrics
SciVal
citations
29
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
FWCI
1.05
SciVal
Author count
5
SciVal
Paper percentile
89
PlumX, opens in new tab
Citation count
42
Captures
92
Funding Details
This research is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA016672 .
FundersFunding number
NIH
-NCI
P30CA016672